Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DC/AML Fusion Cell Vaccine With or Without Decitabine Following Allogeneic Transplantation in AML Patients
NCT03679650Phase 1Active, not recruiting
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- Oct 2018
- Primary completion
- Mar 2026
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of autologous dendritic cell-tumor fusion vaccine in acute myeloid leukemia (AML) (2 arms), sponsored by Beth Israel Deaconess Medical Center. Primary endpoint: Fold-increase in AML specific T cells in peripheral blood and bone marrow at 12 months. Started Oct 2018; status: active, not recruiting.
02
Drugs
autologous dendritic cell-tumor fusion vaccine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03679650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03679650.